140 related articles for article (PubMed ID: 12859444)
1. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies.
Roumestan C; Henriquet C; Bousquet J; Mathieu M
Clin Exp Allergy; 2003 Jul; 33(7):895-901. PubMed ID: 12859444
[TBL] [Abstract][Full Text] [Related]
2. Transrepression and transactivation potencies of inhaled glucocorticoids.
Dirks NL; Li S; Huth B; Hochhaus G; Yates CR; Meibohm B
Pharmazie; 2008 Dec; 63(12):893-8. PubMed ID: 19177906
[TBL] [Abstract][Full Text] [Related]
3. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
4. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate.
Austin RJ; Maschera B; Walker A; Fairbairn L; Meldrum E; Farrow SN; Uings IJ
Eur Respir J; 2002 Dec; 20(6):1386-92. PubMed ID: 12503693
[TBL] [Abstract][Full Text] [Related]
5. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.
Crim C; Pierre LN; Daley-Yates PT
Clin Ther; 2001 Sep; 23(9):1339-54. PubMed ID: 11589253
[TBL] [Abstract][Full Text] [Related]
6. Fluticasone furoate is more effective than mometasone furoate in restoring tobacco smoke inhibited SOCS-3 expression in airway epithelial cells.
Nasreen N; Gonzalves L; Peruvemba S; Mohammed KA
Int Immunopharmacol; 2014 Mar; 19(1):153-60. PubMed ID: 24434372
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional potencies of inhaled glucocorticoids.
Jaffuel D; Demoly P; Gougat C; Balaguer P; Mautino G; Godard P; Bousquet J; Mathieu M
Am J Respir Crit Care Med; 2000 Jul; 162(1):57-63. PubMed ID: 10903220
[TBL] [Abstract][Full Text] [Related]
8. Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms.
Roumestan C; Henriquet C; Gougat C; Michel A; Bichon F; Portet K; Jaffuel D; Mathieu M
Clin Exp Allergy; 2008 Jun; 38(6):947-56. PubMed ID: 18498541
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway.
Escotte S; Tabary O; Dusser D; Majer-Teboul C; Puchelle E; Jacquot J
Eur Respir J; 2003 Apr; 21(4):574-81. PubMed ID: 12762338
[TBL] [Abstract][Full Text] [Related]
10. Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.
Zhang N; Van Crombruggen K; Holtappels G; Lan F; Katotomichelakis M; Zhang L; Högger P; Bachert C
PLoS One; 2014; 9(4):e93754. PubMed ID: 24710117
[TBL] [Abstract][Full Text] [Related]
11. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[TBL] [Abstract][Full Text] [Related]
12. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement.
Adcock IM; Nasuhara Y; Stevens DA; Barnes PJ
Br J Pharmacol; 1999 Jun; 127(4):1003-11. PubMed ID: 10433509
[TBL] [Abstract][Full Text] [Related]
13. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism.
Vanden Berghe W; Francesconi E; De Bosscher K; Resche-Rigon M; Haegeman G
Mol Pharmacol; 1999 Oct; 56(4):797-806. PubMed ID: 10496964
[TBL] [Abstract][Full Text] [Related]
14. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.
Tayab ZR; Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ; Hochhaus G
Br J Clin Pharmacol; 2007 Nov; 64(5):698-705. PubMed ID: 17509041
[TBL] [Abstract][Full Text] [Related]
16. Basic research on virus-induced asthma exacerbation: inhibition of inflammatory chemokine expression by fluticasone propionate.
Matsukura S; Kurokawa M; Homma T; Watanabe S; Suzuki S; Ieki K; Takeuchi H; Notomi K; Schleimer RP; Kawaguchi M; Kokubu F
Int Arch Allergy Immunol; 2013; 161 Suppl 2(Suppl 2):84-92. PubMed ID: 23711858
[TBL] [Abstract][Full Text] [Related]
17. Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids.
Ray KP; Farrow S; Daly M; Talabot F; Searle N
Biochem J; 1997 Dec; 328 ( Pt 2)(Pt 2):707-15. PubMed ID: 9371735
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.
Salter M; Biggadike K; Matthews JL; West MR; Haase MV; Farrow SN; Uings IJ; Gray DW
Am J Physiol Lung Cell Mol Physiol; 2007 Sep; 293(3):L660-7. PubMed ID: 17575011
[TBL] [Abstract][Full Text] [Related]
19. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells.
Chu S; Nishi Y; Yanase T; Nawata H; Fuller PJ
Mol Endocrinol; 2004 Aug; 18(8):1919-28. PubMed ID: 15155785
[TBL] [Abstract][Full Text] [Related]
20. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo.
Baumann D; Bachert C; Högger P
Clin Exp Allergy; 2009 Oct; 39(10):1540-50. PubMed ID: 19538495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
